An observational study in Portal Hypertension, Gastroesophageal Varices Hemorrhage and Gastric Varices, sponsored by Shanghai Zhongshan Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-31.
Sponsored by Shanghai Zhongshan Hospital · Observational
This study aims to evaluate the impact of high-risk factors-such as elevated portal venous pressure, concurrent large extra-luminal vessels, portal vein thrombosis, and prominent portosystemic shunts-on the efficacy of endoscopic therapy. By comparing with interventional treatment, the goal is to optimize the clinical management protocol for esophageal and gastric varices, enhance the therapeutic outcomes of portal hypertension-related esophageal and gastric varices, and improve patient prognosis.
332 studies on the registry are indexed under Hypertension, Portal; 106 are open to participants now.
This study's planned enrollment of 1,066 is above the median of 152 across 119 observational studies indexed under Hypertension, Portal.
Browse Hypertension, Portal studies →Shanghai Zhongshan Hospital is the lead sponsor of 636 studies on the registry; 283 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Enrolled were patients who presented to Zhongshan Hospital, Fudan University and other study centers due to esophagogastric variceal bleeding secondary to portal hypertension between December 2025 and December 2026.
Exclusion Criteria:
The patient underwent Transjugular Intrahepatic Portosystemic Shunt (TIPS) after admission
The patient only received endoscopic treatment after admission.
1-year gastrointestinal rebleeding rate
Time from initial variceal bleeding treated with endoscopy or TIPS to recurrent variceal rupture and bleeding due to portal hypertension (at least 120 hours)
Time frame: 1 year after the treatment.
2-month and 6-month gastrointestinal rebleeding rates
Time from initial variceal bleeding treated with endoscopy or TIPS to recurrent variceal rupture and bleeding due to portal hypertension (at least 120 hours)
Time frame: 2 months and 6 months after the treatment
Indicators in the Child-Pugh classification include the progression of ascites and changes in bilirubin levels.
Depth of abdominal fluid dark area detected by abdominal ultrasound; changes in serum bilirubin levels in liver function tests.
Time frame: 1, 2, 6, and 12 months after the treatment.
Changes of portal vein thrombosis
Evaluate the occurrence, recanalization, and other changes in thrombosis every 6 months using portal CTA and ultrasound.
Time frame: 6 and 12 months after the treatment.
Liver cancer
Hepatocellular carcinoma or cholangiocarcinoma
Time frame: Up to 12 months after the treatment.
Liver transplantation
Based on comprehensive clinical evaluation, liver transplantation is required.
Time frame: Up to 12 months after the treatment.
Variceal bleeding-related mortality
During the follow-up period, deaths caused by variceal rupture and bleeding that occurred within 6 weeks after the bleeding episode and were clearly related to the bleeding, including hemorrhagic shock and multiple organ failure.
Time frame: Up to 12 months after the treatment.
Liver-related mortality
Deaths resulting from variceal rupture and bleeding, liver failure, hepatic encephalopathy, infection, hepatorenal syndrome, etc., excluding deaths due to extrahepatic causes, including: accidental death, cardiovascular events, and deaths caused by other systemic cancers.
Time frame: Up to 12 months after the treatment.
No study locations are listed for this record.
Plan to share: Yes
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Zhongshan Hospital